A
Andrei Pikalov
Researcher at Sunovion
Publications - 134
Citations - 2980
Andrei Pikalov is an academic researcher from Sunovion. The author has contributed to research in topics: Lurasidone & Aripiprazole. The author has an hindex of 28, co-authored 120 publications receiving 2583 citations. Previous affiliations of Andrei Pikalov include University of Pennsylvania & Otsuka Pharmaceutical.
Papers
More filters
Journal ArticleDOI
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Herbert Y. Meltzer,Josephine Cucchiaro,Robert Silva,Masaaki Ogasa,Debra Phillips,Jane Xu,Amir H Kalali,Edward Schweizer,Andrei Pikalov,Antony Loebel +9 more
TL;DR: Treatment with both doses of lurasidone or with olanzapine was associated with significantly greater improvement at week 6 on Positive and Negative Syndrome Scale (PANSS) total score, PANSS positive and negative subscale scores, and CGI-S score compared with placebo.
Journal ArticleDOI
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial☆
Antony Loebel,Josephine Cucchiaro,Kaushik Sarma,Lei Xu,Chuanchieh Hsu,Amir H Kalali,Andrei Pikalov,Steven G. Potkin +7 more
TL;DR: Treatment with both doses of lurasidone or with QXR-600 mg was associated with significantly greater improvement at Week 6 on PANSS total score, PANSS positive and negative subscale scores, and CGI-S score compared with placebo.
Journal ArticleDOI
Akathisia: an updated review focusing on second-generation antipsychotics.
John M. Kane,W. Wolfgang Fleischhacker,Lars K. Hansen,Roy H. Perlis,Andrei Pikalov,Sheila Assunção-Talbott +5 more
TL;DR: Akathisia remains a concern with the use of SGAs and more accurate and standardized evaluations are required for a better understanding of the nature and incidence of akath isia.
Journal ArticleDOI
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
John M. Kane,Christoph U. Correll,Donald C. Goff,Brian Kirkpatrick,Stephen R. Marder,Estelle Vester-Blokland,Wei Sun,William H. Carson,Andrei Pikalov,Sheila Assunção-Talbott +9 more
TL;DR: The addition of aripiprazole to risperidone or quetiapine or quetzalcolytic combination therapy was not associated with improvement in psychiatric symptoms but was generally safe and well tolerated.
Journal ArticleDOI
Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study
Trisha Suppes,Robert Silva,Josephine Cucchiaro,Yongcai Mao,Steven D. Targum,Caroline Streicher,Andrei Pikalov,Antony Loebel +7 more
TL;DR: Lurasidone was effective and well tolerated in this study involving patients with major depressive disorder associated with subthreshold hypomanic symptoms (mixed features) and significant improvement in manic symptoms, assessed by the Young Mania Rating Scale, was also observed.